Airo Brands, a US multi-state CPG company focused on proprietary cannabis products, in partnership with Jupiter Research LLC, has received regulatory approval for its CE-marked Class IIa medical handheld liquid inhalation device, the Airo Medical Inhalation System, across Europe and Australia.
This planned launch will introduce the second EU-certified device of its kind, designed specifically for the delivery of cannabinoid-based medicines under strict medical standards.
This milestone will mark the entry of a precision-engineered device into regulated medical markets, supported by a strategic partnership with SOMAÍ, which will manufacture EU-GMP inhalation oils and serve as the exclusive global distributor for the system’s cartridge line and API’s.
The Airo medical inhalation device is built in full compliance, offering a rechargeable, CE-certified platform engineered for precision, safety, and regulatory integrity.
Its ergonomically rounded design ensures comfort and ease of use—critical factors for patients managing chronic therapies.
This user-friendly form factor will not only support better patient adherence but will also allow for discreet, consistent dosing with confidence.
October 28, 2025 No Comments
October 28, 2025 No Comments
October 27, 2025 No Comments
“Airo Brands, in connection with Jupiter Research received European regulatory approval for this new medical device — a pivotal step in our global expansion,” stated Richard Yost, CEO and Founder Airo Brands.
“This milestone makes Airo one of the first US cannabis companies with a truly international footprint, spanning the US, Europe, and additional markets such as Australia and the UK. Built on medical-grade reliability and consumer-driven innovation, Airo is now poised to deliver best-in-class products worldwide.”
[ATTACH type="full" alt="Somai Pharmaceuticals Logo
"]11159[/ATTACH]
“This partnership reflects what the future of medical cannabis should look like: EU-certified medical devices with EU-GMP API’s in finished dosage formats,” said Michael Sassano, CEO of SOMAÍ Pharmaceuticals.
“We are proud to support Airo’s international expansion by producing stable, EU-GMP inhalation oils and delivering them across compliant medical channels.”
Somaí will produce and fill the EU-GMP-certified cartridges for the medical inhalation device at its pharmaceutical manufacturing facility in Lisbon, Portugal. These extracts have been developed and validated with EU-GMP manufacturing and shelf stability of a minimum of one year, a benchmark rarely achieved in the inhalation category.
With regulatory approvals and infrastructure already in place, the system is ready for launch in key European countries like Germany, as well as other countries like the UK and Australian markets, with additional jurisdictions in the pipeline.
Airo and Somaí are also preparing to collaborate with global cannabis brands to develop therapeutically differentiated cartridges, tailored for specific patient needs. These future releases will be manufactured and distributed under the same EU-GMP-certified and CE-compliant framework—setting a new benchmark for medical-grade vaporisation worldwide.
The post Airo Brands Announces CE-Certified Medical Inhalation Device in Partnership with SOMAÍ appeared first on Business of Cannabis.
Continue reading...
This planned launch will introduce the second EU-certified device of its kind, designed specifically for the delivery of cannabinoid-based medicines under strict medical standards.
This milestone will mark the entry of a precision-engineered device into regulated medical markets, supported by a strategic partnership with SOMAÍ, which will manufacture EU-GMP inhalation oils and serve as the exclusive global distributor for the system’s cartridge line and API’s.
The Airo medical inhalation device is built in full compliance, offering a rechargeable, CE-certified platform engineered for precision, safety, and regulatory integrity.
Its ergonomically rounded design ensures comfort and ease of use—critical factors for patients managing chronic therapies.
This user-friendly form factor will not only support better patient adherence but will also allow for discreet, consistent dosing with confidence.
New York Cannabis Retailers Push Back on $30m Product Recall and ‘Rent-a-Licence’ Scandal
Read More »October 28, 2025 No Comments
Germany Expands Its Medical Cannabis Import Cap as Australia Moves to Cut Back
Read More »October 28, 2025 No Comments
Early Results From Züri Can Pilot Bolster Case for Switzerland’s Federal Legalisation
Read More »October 27, 2025 No Comments
“Airo Brands, in connection with Jupiter Research received European regulatory approval for this new medical device — a pivotal step in our global expansion,” stated Richard Yost, CEO and Founder Airo Brands.
“This milestone makes Airo one of the first US cannabis companies with a truly international footprint, spanning the US, Europe, and additional markets such as Australia and the UK. Built on medical-grade reliability and consumer-driven innovation, Airo is now poised to deliver best-in-class products worldwide.”
[ATTACH type="full" alt="Somai Pharmaceuticals Logo
"]11159[/ATTACH]
“This partnership reflects what the future of medical cannabis should look like: EU-certified medical devices with EU-GMP API’s in finished dosage formats,” said Michael Sassano, CEO of SOMAÍ Pharmaceuticals.
“We are proud to support Airo’s international expansion by producing stable, EU-GMP inhalation oils and delivering them across compliant medical channels.”
Somaí will produce and fill the EU-GMP-certified cartridges for the medical inhalation device at its pharmaceutical manufacturing facility in Lisbon, Portugal. These extracts have been developed and validated with EU-GMP manufacturing and shelf stability of a minimum of one year, a benchmark rarely achieved in the inhalation category.
With regulatory approvals and infrastructure already in place, the system is ready for launch in key European countries like Germany, as well as other countries like the UK and Australian markets, with additional jurisdictions in the pipeline.
Airo and Somaí are also preparing to collaborate with global cannabis brands to develop therapeutically differentiated cartridges, tailored for specific patient needs. These future releases will be manufactured and distributed under the same EU-GMP-certified and CE-compliant framework—setting a new benchmark for medical-grade vaporisation worldwide.
The post Airo Brands Announces CE-Certified Medical Inhalation Device in Partnership with SOMAÍ appeared first on Business of Cannabis.
Continue reading...
